SNMMI is a global and collaborative scientific organization dedicated to both the practice and the science of nuclear medicine and molecular imaging and therapy around the world. SNMMI's worldwide membership totals more than 15,000, including physicians, scientists, technologists, chemists, radiopharmacists, students and industry representatives from 82 countries around the world.
Emerging technologies, the latest clinical applications, best practices, and more are waiting for you. The 2022 Virtual SNMMI Mid-Winter and ACNM Annual Meeting will feature three educational tracks highlighting the latest innovations and techniques in the field, including a dedicated track on cardiovascular nuclear medicine.
Unfortunately, the ongoing COVID-19 global pandemic and surging Omicron variant have forced us to cancel our planned in-person event in Orlando. We are excited to announce that a Virtual 2022 SNMMI Mid-Winter and ACNM Annual Meeting will now take place Friday, February 25 through Sunday, February 27, 2022. Read the full announcement.
Make your plans to attend the SNMMI Therapeutics Conference, in-person, March 10-12, 2022 at the Hyatt Regency New Orleans. This two-and-a-half-day event will explore the latest innovations and clinical applications in radiopharmaceutical therapy.
The SNMMI Annual Meeting—widely recognized as the premier educational, scientific, research, and networking event in nuclear medicine and molecular imaging—is now accepting registrations.
This year, the Annual Meeting will offer both remote and in-person full meeting registration options, allowing you to customize your meeting attendance. Make your plans now to attend SNMMI's flagship meeting, in-person June 11-14 in Vancouver, BC, Canada, or virtually from your home or office.
SNMMI is a global and collaborative scientific organization dedicated to both the practice and the science of nuclear medicine and molecular imaging and therapy around the world. SNMMI's worldwide membership totals over 20,000, which includes physicians, scientists, technologists, chemists, radiopharmacists, students and industry representatives from more than 84 countries around the world. SNMMI's Journal of Nuclear Medicine (JNM), the premier international journal of nuclear medicine, reaches over 17,000 individuals each month. SNMMI's Annual Meeting is nuclear medicine's and molecular imaging's largest gathering each year, attracting over 5,000 professional attendees and another 2,500 industry representatives.
At the most recent Annual Meeting in June 2016 in San Diego, California, 35% of registered attendees were from countries other than the United States. Attendees represented over 65 countries. In addition, abstract submissions for SNMMI's Annual Meeting from outside the United States represent close to 67% of all submissions.
While SNMMI's headquarters office resides in Virginia, just outside of Washington, D.C., its perspective, programs, and growth are as international as its members. As of 2017, 12% of the Society's members reside in more than 84 countries other than the United States.
Search for an international nuclear medicine and molecular imaging organization near you.
SNMMI's educational programs and activities reflect the increasing importance and participation of its international members. Such common global nuclear medicine and molecular imaging and therapy issues as quality of care, educating referring physicians and patients, and exploring ways to better share developments in the practice of nuclear medicine and molecular imaging and therapy are but a few of the activities currently underway by Society staff, Committees, Councils, and our Centers of Excellence. This website seeks to constantly expand its offerings to the Society's international members, providing an ever-changing, updated array of global resources and news for nuclear medicine and molecular imaging and therapy professionals literally anywhere on the globe.
SNMMI continues to stay actively involved in several jointly sponsored educational programs and educational outreach activities with regional nuclear medicine and molecular imaging and therapy organizations around the world; both in their home countries, and during SNMMI's Annual Meeting. These joint sponsored programs include not only the sharing of speakers and renown experts on all facets of nuclear medicine and molecular imaging, collaboration on the development of enduring educational materials, and programmatic/administrative support, but also include translation of materials and website development.
Each year, the SNMMI collaborates with international organizations in an effort to continue the exchange of ideas, education and knowledge. Intiatives include:
Nuclear Medicine Global Initiative
3rd Sino-American Conference
Chinese/U.S. Resident Exchange Program
IAEA CT Case Webinar Series
EANM Collaborative Guidelines
SNMMI offers a Full International Membership category for international colleagues. Learn more on how to become an SNMMI Full Member (international).
Available to physicians, scientists or pharmacists possessing an advanced degree who have presented credentials indicating their professional activity, either, medical, paramedical, investigational or educational in the scientific or clinical disciplines of molecular imaging or nuclear medicine. This includes the diagnostic, therapeutic or investigational use of radionuclides or other molecular imaging technologies.
Annual dues: $510
Includes subscription to The Journal of Nuclear Medicine.
Includes voting rights and can be elected an Officer of the SNMMI.
Corresponding Country Discount
In an effort to make membership more accessible to nuclear medicine and molecular imaging professionals around the world, SNMMI’s corresponding country category gives members of eligible countries an 80% discount on dues. See discount breakdown.
80% discount on all membership categories
Online access to The Journal of Nuclear Medicine.
Voting rights and can be elected an Officer of the SNMMI.
As part of its continuing commitment to growing the practice of nuclear medicine and molecular imaging and therapy worldwide, SNMMI leadership works diligently to develop strategic alliances with key regional nuclear medicine organizations to assist these groups in expanding the scope and quality of nuclear medicine outside the United States. These strategic alliances stretch across the globe. reaching every continent where SNMMI's members reside and practice.
SNMMI Partners and Alliances Include:
For more information on SNMMI's international activities and programs, please contact:
Nikki Wenzel-Lamb, MBA Director of Leadership Direct: 703-652-6766 Fax: 703-708-9020 Email: email@example.com
Gerald DeNardo, MD, professor emeritus of internal medicine and radiology at the University of California–Davis, passed away on February 11, 2024.
Nuclear medicine has the potential to change the landscape of theranostics in neurooncology, according to a new article in JNM. With recent advances in techniques to permeate the brain-blood barrier, the prospect of using radiopharmaceuticals to treat brain tumors is promising.
PRRT is effective for clinical control of symptomatic metastatic insulinomas, according to new research published in JNM. In the largest study to date of metastatic insulinoma patients treated with PRRT, more than 80 percent of patients had long-lasting symptom control, and nearly 60 percent were able to reduce the use of other drugs to treat the disease.
A novel PET imaging technique can noninvasively detect active inflammation in the body —such as rheumatoid arthritis—before clinical symptoms arise, according to research published in JNM.